HER2-Negative Breast Cancer Terminated Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00194792Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerTreatment